Drug delivery system for treatment of cancer
US-2022257525-A1 · Aug 18, 2022 · US
PACA and cabazitaxel for anti-cancer treatment
US11806330B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11806330-B2 |
| Application number | US-201916366596-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 27, 2019 |
| Priority date | Mar 27, 2018 |
| Publication date | Nov 7, 2023 |
| Grant date | Nov 7, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treatment of cancer in a subject, the method comprising intraperitoneally injecting the subject with a poly (alkyl cyanoacrylate) nanoparticle, the nanoparticle comprising 6 to 20 wt % cabazitaxel based on the total weight of the nanoparticle and having a size of 10 to 500 nanometers, wherein the nanoparticle does not include a targeting moiety, wherein the cabazitaxel is encapsulated by the nanoparticle, and wherein the nanoparticle is administered to the subject in an amount sufficient to treat the cancer in the subject, wherein the cancer is peritoneal carcinomatosis originating from ovarian cancer, colorectal carcinoma, cervical cancer, breast cancer, colon cancer, or prostate cancer, or is pseudomyxoma peritonei, and wherein the poly(alkyl cyanoacrylate) comprises a cyanoacrylate having a 2-ethyl butyl (EBCA) alkyl chain. 2. The method of claim 1 , wherein the nanoparticle is administered in an amount sufficient to inhibit the metastasis of the cancer in the subject and the method comprises inhibiting metastasis in the subject. 3. The method of claim 1 , wherein the nanoparticle is produced according to a miniemulsion anionic polymerization process. 4. The method of claim 3 , wherein the nanoparticle has a particle size of 70 to 150 nanometers. 5. The method of claim 3 , wherein the nanoparticle is PEGylated. 6. The method of claim 1 , wherein intraperitoneally injecting is subsequent to cytoreductive surgery. 7. The method of claim 1 , wherein the cancer is peritoneal carcinomatosis originating from ovarian cancer or colorectal carcinoma, or is pseudomyxoma peritonei.
Assignees
Inventors
Classifications
- A61K31/337Primary
having four-membered rings, e.g. taxol · CPC title
- A61K9/0019Primary
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers · CPC title
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11806330B2 cover?
- Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.
- Who is the assignee on this patent?
- Sintef Tto As, Univ Oslo Hf
- What technology area does this patent fall under?
- Primary CPC classification A61K31/337. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).